The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - AbbVie
Open-label, dose-escalation, phase 1 study of venetoclax in combination with navitoclax and chemotherapy in patients with relapsed acute lymphoblastic leukemia.
 
Thomas Alexander
No Relationships to Disclose
 
Seong Lin Khaw
Research Funding - Abbvie (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Novartis
 
Jeffrey E. Rubnitz
No Relationships to Disclose
 
Susan I. Vear
No Relationships to Disclose
 
Norman James Lacayo
No Relationships to Disclose
 
Michelle Schmidt
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Bo Tong
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Lindsey Rosenwinkel
Employment - Abbvie
 
Lindsey Bensman
Employment - AbbVie
Stock and Other Ownership Interests - Abbvie
 
Maria Verdugo
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Su Young Kim
Employment - AbbVie
Stock and Other Ownership Interests - Abbvie
 
Elias Jabbour
Consulting or Advisory Role - Pfizer
Research Funding - Pfizer
 
Wendy Stock
Honoraria - ADC Therapeutics; amgen; Gilead Sciences; Pfizer
Research Funding - Sigma-Tau (Inst)
Patents, Royalties, Other Intellectual Property - Royalties for a chapter in Up to Date